5-methyl-N1-phenylbenzene-1,2-diamine | 105972-26-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-methyl-N1-phenylbenzene-1,2-diamine
• 英文别名: 5-Methyl-2-amino-diphenylamin；4-methyl-N²-phenyl-o-phenylenediamine；4-Methyl-N²-phenyl-o-phenylendiamin；4-Amino-3-anilino-toluol；4-methyl-N2-phenylbenzene-1,2-diamine；6-Amino-3-methyl-diphenylamin；4-methyl-2-N-phenylbenzene-1,2-diamine
• CAS: 105972-26-7
• 化学式: C₁₃H₁₄N₂
• 分子量: 198.268
• InChiKey: IZCRFJSMFHZEJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-methyl-N1-phenylbenzene-1,2-diamine 在 N-甲基吗啉 、 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 61.67h， 生成 (S)-N-(1-(6-methyl-1-phenyl-1H-benzo[d]imidazol-2-yl)ethyl)-9H-purin-6-amine
  参考文献：
  名称：

  HETEROCYCLIC COMPOUNDS AND METHODS OF USE

  摘要：

  化学式I类化合物，包括立体异构体、几何异构体、互变异构体、代谢物及其药学上可接受的盐，对抑制PI3K的δ异构体以及治疗由脂质激酶介导的疾病，如炎症、免疫性疾病和癌症，具有用途。公开了利用化合物I类进行体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这类疾病，或相关的病理状况的方法。

  公开号：

  US20120202785A1
• 作为产物：
  描述：

  苯胺 在 palladium 10% on activated carbon 氢气 作用下， 以 二甲基亚砜 、 乙酸乙酯 为溶剂， 反应 25.0h， 生成 5-methyl-N1-phenylbenzene-1,2-diamine
  参考文献：
  名称：

  HETEROCYCLIC COMPOUNDS AND METHODS OF USE

  摘要：

  化学式I类化合物，包括立体异构体、几何异构体、互变异构体、代谢物及其药学上可接受的盐，对抑制PI3K的δ异构体以及治疗由脂质激酶介导的疾病，如炎症、免疫性疾病和癌症，具有用途。公开了利用化合物I类进行体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这类疾病，或相关的病理状况的方法。

  公开号：

  US20120202785A1

文献信息

• AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE
  申请人：McComas Casey Cameron

  公开号：US20080161366A1

  公开（公告）日：2008-07-03

  The present invention is directed to aminoalkyl-substituted aryl sulfamide derivatives of formula I: or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic neuropathy, pain, and other diseases or disorders.

  本发明涉及公式I的氨基烷基取代芳基磺酰胺衍生物，或其药学上可接受的盐、立体异构体或互变异构体，它们是单胺再摄取抑制剂，包含这些衍生物的组合物，以及它们用于预防和治疗症状，包括但不限于血管运动症状、性功能障碍、胃肠障碍和泌尿生殖障碍、抑郁症、内源性行为障碍、认知障碍、糖尿病神经病变、疼痛和其他疾病或障碍的方法。
• Heterocyclic compounds and methods of use
  申请人：Heald Robert

  公开号：US08653089B2

  公开（公告）日：2014-02-18

  Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  包括立体异构体、几何异构体、互变异构体、代谢物和药学上可接受的盐在内的公式I化合物，可用于抑制PI3K的δ异构体，并用于治疗由脂质激酶介导的疾病，如炎症、免疫性疾病和癌症。本文揭示了使用公式I化合物进行哺乳动物细胞内、原位和体内诊断、预防或治疗此类疾病或相关病理状态的方法。
• Benzimidazole derivatives and uses thereof
  申请人：Peloton Therapeutics, Inc.

  公开号：US10040767B2

  公开（公告）日：2018-08-07

  Benzimidazole derivatives of Formula I, that modulate the activity of ACSS2 are disclosed for therapeutic use. The fused imidazole ring of the compounds disclosed has a diarylmethyl or diarylmethanol moiety attached at the 2-position and the as compounds have at least one other substituent at the 5 or 6 position of the benzimidazole. Also disclosed are methods of using the benzimidazole compounds for the treatment of diseases or disorders, such as cancer.

  本研究公开了可调节 ACSS2 活性的式 I 苯并咪唑衍生物，用于治疗。所公开化合物的融合咪唑环在 2 位上连接有二芳基甲基或二芳基甲醇分子，而作为化合物的苯并咪唑在 5 或 6 位上至少有一个其他取代基。还公开了使用苯并咪唑化合物治疗疾病或紊乱（如癌症）的方法。
• Ni-Catalyzed Dual C–H Annulation of Benzimidazoles with Alkynes for Synthesis of π-Extended Heteroarenes
  作者：Shao-Long Qi、Yue Li、Jiang-Fei Li、Tao Zhang、Yu-Xin Luan、Mengchun Ye

  DOI：10.1021/acs.orglett.1c01253

  日期：2021.5.21
• Structure−Activity Relationships for 1-Phenylbenzimidazoles as Selective ATP Site Inhibitors of the Platelet-Derived Growth Factor Receptor
  作者：Brian D. Palmer、Jeff B. Smaill、Maruta Boyd、Diane H. Boschelli、Annette M. Doherty、James M. Hamby、Sonya S. Khatana、James B. Kramer、Alan J. Kraker、Robert L. Panek、Gina H. Lu、Tawny K. Dahring、R. Thomas Winters、H. D. Hollis Showalter、William A. Denny

  DOI：10.1021/jm9804681

  日期：1998.12.1

  1-Phenylbenzimidazoles are shown to be a new class of ATP-site inhibitors of the platelet-derived growth factor receptor (PDGFR). Structure-activity relationships (SARs) are narrow, with closely related heterocycles being inactive. A systematic study of substituted 1-phenyl-benzimidazoles showed clear SARs. Substituents at the 4'- and 3'-positions of the phenyl ring are tolerated but do not significantly improve activity, while substituents at the 2'-position abolish it. Substituents in the 2-, 4-, and 7-positions of the benzimidazole ring (with the exception of 4-OH) also abolish activity. Most substituents at the 5- and B-positions maintain or increase activity, with the 5-OH, 5-OMe, 5-COMe, and 5-CO2Me analogues being >10-fold more potent than the parent 1-phenylbenzimidazole. The 5-OMe analogue was both the most potent inhibitor, and showed the highest selectivity (50-fold) between PDGFR and FGFR isolated enzymes, and also a moderately effective inhibitor (IC50 = 1.9 mu M) of PDGF-stimulated PDGFR autophosphorylation in rat aorta smooth muscle cells.